Comparison · NCT00458393-9d472ac5
TDF/FTC vs Placebo: Incidence of HSV-2 During the Follow-up Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TDF/FTC vs Placebo: Incidence of HSV-2 During the Follow-up Period. Trial comparisons, record NCT00458393-9d472ac5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00458393-9d472ac5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0969 | 0.0767 | 0.122 | wilson | |
| Risk in group 2 | 0.0888 | 0.0696 | 0.113 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00811 | -0.0231 | 0.0394 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 0.781 | 1.52 | log | |
| Odds ratio, group 1 over group 2 | 1.1 | 0.762 | 1.59 | log | |
| Number needed to treat, for one more participant with the outcome on TDF/FTC than on Placebo | 123 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TDF/FTC | Daily oral emtricitabine/tenofovir disoproxil fumarate | 65 | 671 | OG000 |
| Group 2 | Placebo | Daily oral placebo | 60 | 676 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of HSV-2 During the Follow-up Period
- Description
- Incidence of HSV-2 during the follow-up period among those HIV-2 negative at baseline
- Time frame
- Total study follow-up, a median of 1.2 years
- Population
- All HSV-2 negative participants with a follow-up HSV-2 test.
Source ClinicalTrials.gov
Trial
- Title
- Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
- NCT number
- NCT00458393
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- daily TDF/FTC, Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2018-01-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00458393?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00458393-9d472ac5